Omeros Corporation

4 hours ago · benzinga.com

Cantor Fitzgerald on Tuesday upgraded Omeros Corp (NASDAQ:OMER), citing a better-than-expected Yartemlea launch.

25 days ago · zacks.com

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

28 days ago · zacks.com

Omeros Corporation (OMER) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OMER's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

4 months ago · marketbeat.com

Omeros NASDAQ: OMER reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA.

4 months ago · seekingalpha.com

Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript

4 months ago · businesswire.com

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include: First Quarter and Recent Highlights In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million. Net income for the first quarter of.

4 months ago · businesswire.com

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click.